MedTrace Logo

Study of Amrubicin in Patients With Small Cell Lung Cancer Refractory or Progressive to Prior Therapy

NCT00375193 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2019-10-24

No results posted yet for this study

Summary

The purpose of the study is to evaluate the objective tumor response rate of amrubicin when administered as second-line therapy to ED-SCLC patients who have refractory or progressive disease.

Conditions

Interventions

DRUG

Amrubicin

Amrubicin 40mg/m\<2\> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Richard S Ungerleider, MD · Theradex

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-01
Primary Completion
2008-05-01
Completion
2009-03-01

Countries

  • United States
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00375193 on ClinicalTrials.gov